Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST

NCT02638766 is registered in ClinicalTrials.gov with Grupo Espanol de Investigacion en Sarcomas as lead sponsor.

NCT NCT02638766
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02638766 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST
Lead sponsor
Grupo Espanol de Investigacion en Sarcomas
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2015
Completion date
August 31, 2021
Enrollment
15 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumors